Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by Montevialeon Dec 31, 2017 10:51am
139 Views
Post# 27254132

RE:RE:RE:RE:MMJ is safe, says WHO - how long will USA Rescheduling take?

RE:RE:RE:RE:MMJ is safe, says WHO - how long will USA Rescheduling take?GTP,

GW Pharmaceuticals has applied for FDA approval of their CBD epilepsy drug Epidiolex.  If accepted it would be the first cannabis formulated medication to receive FDA approval.   From what I’ve read, by law the FDA/DEA will have 90 days to reschedule it from a schedule 1 drug after its approval.  The approval and rescheduling of cannabis derived CBD would mean that for the very first time the US federal government would be admitting that CBD has medical value.  The public pressure from media attention and the hypocrisy-surrounding schedule 1 will force the government to reschedule cannabis. 
 
The FDA is expected to rule on Epidiolex sometime between May / July of 2018.  If it gets approved, which many are expecting, this should act as a very strong catalyst to the cannabis industry and all pharm companies doing research that involves CBD.  Hint… Kalytera. 

If FDA approves GW's application in May/July of 2018 it will be the equivalent of throwing gasoline onto a fire when it comes to Canadian cannabis stocks.  It will me a major catalyst if not a super catalyst for cannabis share prices in Canada that will already be on fire because of pending legalization.  

Look for Cannabis to get rescheduled in the second half of 2018.  

Happy new years to you and yours.  

Monteviale


Gonetopot wrote: Sunny how sure can we be that the USA will make changes in 2018? Happy New Year to you and your family.


Bullboard Posts